Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This pilot trial studies how well leflunomide works for the treatment of patients with
high-risk smoldering plasma cell myeloma, for the delay of disease progression.
Anti-inflammatory drugs, such as leflunomide lower the body's immune response and are used
with other drugs in the treatment of some types of cancer. The information learned from this
study will help researchers to learn more about the anti-myeloma activity of leflunomide, and
whether it may delay the onset of symptomatic multiple myeloma in patients with high-risk
smoldering multiple myeloma.